Pharmacokinetically guided dosing of mycophenolate mofetil for pediatric lupus nephritis
Official title: The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Funded at Cincinnati Childrens Hosp Med Ctr · NIH-11333765 · Data updated 2026-11-12
A kid-focused trial will test whether adjusting mycophenolate mofetil dosing by pharmacokinetics improves kidney remission for children with proliferative lupus nephritis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | July 15, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $534,933 |
| NIH project number | 5R01AR079124-05 |
| Project ID | NIH-11333765 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants are children with proliferative lupus nephritis eligible for MMF therapy.
✕Less likely to help
Patients not meeting inclusion criteria or those unable to tolerate MMF may not benefit.
What this research studies
This trial enrolls children with proliferative lupus nephritis to compare pharmacokinetically guided MMF dosing against conventional weight-based dosing over 104 weeks. It is a randomized, double-blind study designed to see if precision dosing leads to better kidney outcomes and acceptable safety in a pediatric population. The primary goal is to measure the proportion achieving partial kidney remission by week 26, with a key secondary goal of complete remission. The study uses careful monitoring to tailor dosing and minimize adverse effects while maintaining treatment efficacy.
Why it matters
Potential benefit: If successful, children with lupus nephritis could experience higher kidney response rates and potentially fewer drug-related problems.
How similar studies have gone: Previous adult data suggest that PK-guided dosing could improve outcomes; this pediatric trial tests that approach directly in kids.
Where this research is happening
-
Cincinnati Childrens Hosp Med Ctr
Cincinnati, United States Active
Researchers
- Principal investigator: Brunner, Hermine I — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Brunner, Hermine I
Related research
Other NIH-funded projects on the same topics.
-
Glycoprotein urine markers that signal lupus nephritis treatment response
A novel test uses urine glycoprotein patterns to show how well lupus nephritis is responding to standard treatment.
-
PTPRS and lupus nephritis: a new target to reduce kidney damage in lupus
Aims to understand how PTPRS contributes to kidney inflammation and scarring in lupus nephritis and explore targeting it to help patients.
-
Sodium’s effect on kidney B cells in lupus kidney disease
This grant explores how high sodium in the kidneys affects B cells in lupus nephritis and whether blocking a key cellular pump could reduce kidney damage.
-
Oral CD11b Activator for Lupus Nephritis
A new oral CD11b activating drug is being explored to help people with lupus nephritis by targeting immune pathways that cause kidney inflammation.
-
Objective classification of lupus nephritis using computer vision
A new computer vision tool uses deep learning to classify lupus nephritis from kidney tissue images to help doctors predict outcomes for patients with lupus.
-
AI-powered look at lupus nephritis in humans and mice
Researchers will use artificial intelligence to compare kidney tissue from people with lupus nephritis to tissue from mouse models, aiming to understand why treatments work differently in humans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.